Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH

This study is a Phase 2 pilot study to characterize and examine the pharmacokinetics and
efficacy profile of Chronocort® in adults with congenital adrenal hyperplasia (CAH). It is
designed as a two-part, single cohort, open label, multiple dose Phase 2 pilot study to:
(Part A) characterize and examine the pharmacokinetics (PK) and disease bio-marker behavior
following short-term dosing with Chronocort®; and to (Part B) examine the disease control
after six months dose titration with Chronocort® in adults with CAH.

Inclusion Criteria:

1. Known CAH due to 21-hydroxylase deficiency (classic CAH) based on hormonal and
genetic testing currently treated with hydrocortisone, prednisone, prednisolone or
dexamethasone on a stable dosage for a minimum of 3 months.

2. Male or female patients aged 18 and above.

3. Provision of signed written informed consent.

4. Good general health.

5. Females of childbearing potential must have a negative pregnancy test initially and
at all visits. Females who are engaging in sexual intercourse must be using a
medically acceptable method of contraception (as defined in the protocol, section
10.5).

6. Plasma renin activity must be within the clinically acceptable range at screening
(less than 1.5 times upper normal range).

Exclusion Criteria:

1. Co-morbid condition requiring daily administration of a medication that induces
hepatic enzymes or interferes with the metabolism of glucocorticoids.

2. Clinical or biochemical evidence of hepatic or renal disease. Creatinine above the
normal range or elevated liver function tests (ALT or AST) > 2 times the upper
limits of normal.

3. Females who are pregnant or lactating.

4. Women taking an estrogen-containing oral contraceptive pill and who have taken it
within 6 weeks of recruitment.

5. Patients taking spironolactone.

6. Patients on inhaled or oral steroids apart from treatment for CAH.

7. Patients with any other significant medical or psychiatric conditions that in the
opinion of the Investigator would preclude participation in the trial.

8. Participation in another clinical trial of an investigational or licensed drug or
device within the 3 months prior to inclusion in this study.

9. Patients with history of bilateral adrenalectomy.